Cargando…
MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
Activating mutations in NRAS are frequent driver events in cutaneous melanoma. NRAS is a GTP-binding protein, whose most well-characterized downstream effector is RAF leading to activation of MEK-ERK1/2 signaling. While there are no FDA-approved targeted therapies for melanoma patients with a primar...
Autores principales: | Vu, Ha Linh, Rosenbaum, Sheera, Capparelli, Claudia, Purwin, Timothy J., Davies, Michael A., Berger, Adam C., Aplin, Andrew E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789776/ https://www.ncbi.nlm.nih.gov/pubmed/26967478 http://dx.doi.org/10.1016/j.jid.2015.11.012 |
Ejemplares similares
-
MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018) -
Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
por: Tiago, Manoela, et al.
Publicado: (2020) -
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015) -
SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
por: Rosenbaum, Sheera R., et al.
Publicado: (2021) -
NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)